Health Canada fast tracks review of multiple sclerosis drug[ ... Read the full report ... ]
Last Updated Mon, 22 Nov 2004 21:28:46 EST
TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the disease.
The drug Antegren prevents white blood cells from migrating to the central nervous system and flooding the brain, where the cells can cause damage.
The study included 942 patients with relapsing-remitting MS, the earliest phase of the disease.
After one year, patients on Antregen had two-thirds fewer relapses or attacks compared to patients given a placebo.
"In general, you can say that this is the greatest therapeutic effects ever seen in year one for a trial of a multiple sclerosis drug," said Dr. Paul O'Connor, the lead Canadian investigator for the trial.
From the elan company website: Antegren/Tysabri (natalizumab).